News >

TOCA 511 and Toca FC Treatment Misses OS Endpoint in Glioma Trial

Gina Columbus
Published: Friday, Sep 13, 2019

Marty Duvall

Marty Duvall

Treatment with Toca 511 and Toca FC did not improve overall survival (OS) compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.1

= .003). Moreover, tumor samples from patients who survived ≥52 weeks after Toca 511 delivery disproportionately displayed a survival-related mRNA expression signature, which identified a potential molecular signature with possible correlation with treatment-related survival versus it being a prognostic factor.


  1. Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer. Tocagen. Published September 12, 2019. Accessed September 12, 2019.
  2. Cloughesy TF, Landolfi J, Hogan DJ, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication